Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy

NCT01715168 is registered in ClinicalTrials.gov with Azaya Therapeutics, Inc. as lead sponsor.

NCT NCT01715168
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01715168 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy
Lead sponsor
Azaya Therapeutics, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2012
Completion date
December 31, 2015
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, malignant female reproductive system neoplasm, ovarian cancer, ovarian epithelial cancer recurrent, ovarian tumor